Date & Time
7:00 pm - 9:00 pm
Anthony Bossis, PhD
Psycho-spiritual and existential distress is often an integral component of end-of-life suffering. Clinical research demonstrates that patients diagnosed with advanced-stage cancer often experience hopelessness, despair, and a loss of meaning. For many individuals, a diagnosis of cancer initiates a search for meaning. This presentation will review the findings and implications from FDA-approved psilocybin-generated mystical experience research. Psilocybin is the psychoactive compound found in specific species of mushrooms. Subjective features of a mystical experience include unity, sacredness, transcendence, ineffability, and a greater connection to deeply felt positive emotions including that of love. The NYU clinical trial investigated the efficacy of a single psilocybin-generated mystical experience in helping individuals with cancer and at the end of life cultivate meaning, enhance existential and spiritual well-being, and foster a greater acceptance of the dying process with less anxiety. The landmark scientific findings of a rapid reduction in depression, anxiety, and myriad forms of distress were published in 2016. Clinical case vignettes from the psilocybin study will be discussed.
- Identify and describe existential and psycho-spiritual distress in cancer patients and at the end-of-life.
- Recognize the importance of meaning and transcendence for a client in existential and end-of-life distress.
- Cite specific research on psilocybin and other psychedelics in psychiatry and end-of-life distress.
- Describe the psilocybin cancer anxiety research model and implications for palliative care.
An Evening Workshop
Friday, June 15, 2018, 7:00 – 9:00 pm
$55 (Members & Nonmembers) Early Bird $45 by 5/18
This course is also part of the Integrative Thanatology Certificate Program
New York Open Center
Anthony Bossis, Ph.D. is a clinical psychologist and Clinical Assistant Professor of Psychiatry at New York University School of Medicine. He was director of palliative care research, co-principal investigator, and a session guide for the NYU Psilocybin Cancer Anxiety Study and is Project Director for the NYU Psilocybin Religious Leaders Study. He maintains a private psychotherapy practice in NYC.